OPTIMIZE IDE for the Treatment of ACS
A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1630 participants.
Also called NCT03190473
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,630 participants
- Sponsor
- Svelte Medical Systems, Inc.
- Registry
-
NCT03190473
-
- Other papers using this trial's data
- Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Results of the OPTIMIZE Randomized Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Japan, Netherlands
- Registry status
- Terminated
Technical summary
Registry record NCT03190473. Randomized; single masking; primary purpose treatment. Start 2018-01-02 (actual); primary completion 2020-07-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- OPTIMIZE IDE for the Treatment of ACS
- Acronym
- OPTIMIZE
- Condition
- Acute Coronary Syndrome
- Intervention (Device)
- DES
- Lead sponsor
- Svelte Medical Systems, Inc.
Record details
- Record id
cardio:ct-nct03190473- Content hash
dc7bb9db9ac6fe933b5e30d16a200765cda4c425257ed771acaa2dd7a88df753